Gregory Weinhoff, M.D., M.B.A., is Chief Financial Officer of Centessa Pharmaceuticals. Most recently, Greg was a Co-Founder and Chief Financial and Chief Business Officer at Arvelle Therapeutics B.V. In that role, he was responsible for sourcing cenobamate, a novel anti-seizure medicine with best-in-class efficacy, negotiating the license with SK Biopharmaceuticals for European rights, and raising a $207.8M startup financing which was one of the largest startup financings for a European biopharma. Greg played a key role in preparing the Arvelle organization for commercialization and driving the strategic sale process which resulted in the $960M acquisition by Angelini Pharma.
Previously, Greg was Chief Financial Officer at Axovant Sciences, Inc. where he oversaw Finance, Accounting, Investor Relations and Business Development. At Axovant, he was the Principal Financial and Accounting Officer for SEC purposes and was responsible for three public financings, a private placement and a venture debt financing.
Before becoming Chief Financial Officer of Axovant, Greg spent fifteen years as an early-stage healthcare venture capitalist at CHL Medical Partners. He was the founding Chief Executive Officer and sole Series A investor in Amicus Therapeutics where he remained a Board member and member of the Audit Committee through its IPO in 2009. Prior to graduate school, Greg was a financial analyst in Morgan Stanley & Co.’s healthcare corporate finance group.
Greg holds an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School, and an A.B. in Economics from Harvard College.
Current role
Chief Financial Officer at Jostle
Chief Financial Officer at Dover Corporation
Chief Financial Officer at Echelon Fitness
Chief Financial Officer at UpSellit | Managed Conversion Optimization
President & Chief Financial Officer at Bridgewater Bank
Access the worlds's biggest network of public org charts
Learn more